Related Experiment Video
Updated: Aug 22, 2025
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials
Brian M Andersen1,2, David A Reardon3
1Department of Neurology, Brigham and Women's Hospital.
Purpose Of Review:
Summarize principles behind various immunotherapy approaches for high and low-grade glioma in the context of recently completed clinical trials and the new insights they provide.
Recent Findings:
Despite the widespread success of therapies targeting the T-cell checkpoints programmed-death 1 and cytotoxic T lymphocyte antigen 4 in other malignancies, recent phase III trials in glioblastoma confirm the lack of efficacy of anti-programmed-death 1 monotherapy in more than 90% of patients. Vaccination approaches remain under investigation for high-grade glioma and have shown activity in some low-grade glioma patients. Chimeric antigen receptor T cells now feature a new generation of products engineered to potentially withstand glucocorticoid therapy. Oncolytic viral therapies have similarly advanced in sophistication, with drug-sensitive gene expression and tumor-selective modifications. Combinations of therapies hold promise for overcoming the numerous mechanisms of immune suppression in glioma.
Summary:
Although immunotherapies have yet to show rates of efficacy compared with other malignancies, new knowledge of immunology and combination therapies brings hope for improved efficacy in the future.
Insights
Immunotherapy for glioma shows limited success, with checkpoint inhibitors ineffective in glioblastoma. Novel approaches like CAR T-cells and oncolytic viruses are advancing, offering future hope through combination therapies.
Area of Science:
- Neuro-oncology
- Immunology
- Clinical Trials
Background:
- Immunotherapy, including T-cell checkpoint inhibitors (programmed-death 1, cytotoxic T lymphocyte antigen 4), has transformed cancer treatment.
- However, its efficacy in high-grade glioma, particularly glioblastoma, remains a significant challenge.
Conclusions:
- Current immunotherapies show suboptimal efficacy in glioma compared to other cancers.
- Advances in understanding glioma immunology and novel therapeutic combinations offer future potential for improved outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...